Tags : divests

Takeda Divests its Select Non-Core Assets in the EU and

Shots: Takeda will receive $562M up front for divesting its non-core prescription pharmaceutical products targeting a variety of therapeutic categories sold predominantly in the EU and Canada The divested portfolio includes Takeda’s CV/ metabolic and anti-inflammatory therapeutic areas along with Calcium. The portfolio generated FY 2019 net sales of ~$260M The divestiture further enables Takeda’s […]Read More

AstraZeneca to Divest Global Rights of Movantik (naloxegol) to RedHill

Shots: AstraZeneca to receive $52.5M up front and a non-contingent payment of $15M in 2021 while RedHill to get global rights of Movantik (Ex- EU, Canada and Israel). The divestiture allows AstraZeneca to focus on main therapy areas and is expected to be completed in Q1’20 AstraZeneca will transfer it 2015 co-commercialization agreement with Daiichi […]Read More

AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to

Shots: AstraZeneca to receive $35M upfront with future sales-contingent payments of up to $6M and it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its portfolio of mature medicines. In earlier 2019, AstraZeneca divested […]Read More

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm

Shots: AstraZeneca to receive $178M up front and up to $61M as sales-contingent payments while it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period. The transaction is expected to be closed in Q4’19 The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its […]Read More

Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Shots: Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B, in all stock transaction with the put option. The transaction is expected to close in H1’19 The focus of the agreement is to allow BMS to emphasize on its portfolio offering treatments in serious diseases and strengthen Taisho’s OTC platform UPSA develops and delivers medicines in multiple therapeutic […]Read More

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi

 Shots: AstraZeneca to get $1.5B upfront ($1B in cash & 0.5B equity) plus $470M sales based milestones for Synagis. AZ has also sold US rights for its new candidate MEDI8897 to Sobi, for $175M milestone for BLA submission plus $110M development milestones & $60M non-contingent payment during 2019-2021 Sobi to get hold of the US […]Read More

AstraZeneca Divests Rights of its Nexium and Vimovo Product to

Shots: AZ will receive an upfront $700M & $115M plus milestone payments up to $90M & $17M for Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) respectively. Grunenthal to get commercialization rights for Nexium in EU & WW rights for Vimovo (except in the US & Japan) AZ will continue to manufacture and supply Nexium under the long-term […]Read More

Novartis divests part of Sandoz US Genercis as well as

Shots: Novartis sells a part of Sandoz US, which includes ~300 products that generated $0.6B in H1’18 This transaction includes development projects along with ~300 products to Aurobindo Pharma USA Inc. for $0.9B in cash & $0.1B of potential earn-outs, with expected closure in 2019 Aurobindo will also take over manufacturing facilities in Wilson, North […]Read More